Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2018

Yoneshima Yasuto, Ijichi Kayo, Anai Satoshi, Ota Keiichi, Otsubo Kohei, Iwama Eiji, Tanaka Kentaro, Oda Yoshinao, Nakanishi Yoichi, Okamoto Isamu

Abstract excerpt

OBJECTIVES: Expression of programmed cell death-ligand 1 (PD-L1) has been associated with clinical outcome of programmed cell death-1 (PD-1) pathway blockade in non-small cell lung cancer (NSCLC). The PD-L1 IHC 22C3 pharmDx assay, the only companion diagnostic for pembrolizumab therapy, has revealed that ∼30% of all NSCLCs express PD-L1 at a high level. The frequency of high PD-L1 expression in NSCLCs with known...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
Anaplastic Lymphoma Kinase
B7-H1 Antigen
ErbB Receptors
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Oncogene Proteins, Fusion

Survival Analysis

Translocation, Genetic

Source

Identifiers

PMID: 29572000
DOI: 10.1016/j.lungcan.2018.01.024

Genes

EGFR
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.PMID 29572000Read ↗

Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.Semantic proximity Read ↗

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.Semantic proximity Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.Semantic proximity Read ↗

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.Semantic proximity Read ↗

Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.Semantic proximity Read ↗

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Semantic proximity Read ↗

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.